Rapid Micro Biosystems, Inc.
RPIDHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframeRapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and. The $39.1M market capitalization puts RPID squarely in micro-cap range for its industry. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.
Market Cap
$39.1M
Beta
1.50
P/E (TTM)
—
P/E (Fwd)
-1.09
EPS (TTM)
$-1.11
EPS (Fwd)
$-0.71
ROE
-141.7%
ROA
-46.4%
Cash
$20.5M
Total Debt
$23.5M
Free CF
-$21.4M
52W Change
-73.6%
Annual Financials
Cash vs Debt
Where RPID stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, RPID finished 57.69% below its 150-day moving average ($1.82) and 67.23% below its 200-day moving average ($2.35). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RPID overbought or oversold?
At the October 20, 2026 close, RPID's RSI(14) was 22.6, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $20.5M in cash, though total debt stands at $23.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$21.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -141.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $17.1M (2022) to $33.6M (2025), reflecting a 96% increase over the period.
A beta of 1.50 means RPID is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Rapid Micro Biosystems, Inc. and its sector.